Conclusions: Thymoquinones’ superior efficacy under hypoxic conditions demonstrates ROS-independent cytotoxic mechanisms; however, the enrichment of CD133+ cells raises essential questions about long-term therapeutic outcomes and the risks of tumor recurrence. This evidence concerns the gene PROM1 and neoplasm.